Where next for inhaled corticosteroids in childhood asthma?

Publication date: Available online 21 January 2020Source: The Lancet Respiratory MedicineAuthor(s): Ian P Sinha, Susanna R Dodd, Christopher Grime, Daniel B Hawcutt, Ricardo M Fernandes, Matthew R Roberts, Justus M Simba, Paula R Williamson
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research

Related Links:

ConclusionsThese findings suggest that glycopyrronium, formoterol, and a combination of glycopyrronium, formoterol, and budesonide inhibit HCoV-229E replication partly by inhibiting receptor expression and/or endosomal function and that these drugs modulate infection-induced inflammation in the airway.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
CONCLUSIONS: Families who were provided a written asthma action plan during their pediatric emergency department visit for an asthma exacerbation reported fewer unplanned visits during the subsequent three months. PMID: 32066290 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
Conclusions Inhaled corticosteroid use is not associated with a reduction in lung cancer incidence in patients with COPD. Observational studies reporting such reduction may have been affected by time-related biases and the inclusion of patients with asthma. The proposition of a randomised trial warrants some caution.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking Original Articles: COPD Source Type: research
Condition:   Asthma Interventions:   Drug: Prednisone/ Prednisolone;   Biological: Mepolizumab;   Drug: Salbutamol Sponsors:   GlaxoSmithKline;   Tech Observer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Theophylline is still one of the most widely prescribed drugs for the treatment of asthma and COPD in developing countries because the majority of asthma and COPD medicines and are largely unavailable and also because it is a cheaper option. In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. In order to overcome the problems posed by theophylline, other xanthines have been developed.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Tags: Review article Source Type: research
Publication date: Available online 14 February 2020Source: The Lancet Respiratory MedicineAuthor(s): Jonathan A Bernstein, J Christian Virchow, Kevin Murphy, Jorge Fernando Maspero, Joshua Jacobs, Yochai Adir, Marc Humbert, Mario Castro, Douglas A Marsteller, Jennifer McElhattan, Lisa Hickey, Margaret Garin, Rebecca Vanlandingham, Guy BrusselleSummaryBackgroundReslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and increased blood eosinophils....
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
ConclusionsSpecialist-diagnosed CC was associated with considerable disease burden, particularly among those with both respiratory disease and GERD. Additionally, CC burden was more pronounced than in matched non-cough patients.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Source: European Respiratory Review - Category: Respiratory Medicine Tags: Author correction Source Type: research
This JAMA Insights Clinical Update reviews management of asthma exacerbations, including the use of inhaled corticosteroids (ICS), azithromycin, magnesium sulfate, and nebulized bronchodilators vs metered-dose inhalers (MDIs), and discusses the potential future role of benralizumab and other biological therapies.
Source: JAMA - Category: General Medicine Source Type: research
More News: Asthma | Corticosteroid Therapy | Respiratory Medicine